Precision BioSciences Announces Appointment Of Gene Liau, Ph.D. And Bruce Mccreedy, Ph.D. To Management Team

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Precision BioSciences, the genome editing company, today announced two key additions to the executive team - Gene Liau, Ph.D., as Senior Vice President, Gene Therapy and Bruce McCreedy, Ph.D., as Senior Vice President, Cell Therapy.

"We are excited to welcome Gene and Bruce to the Precision team," said Matthew Kane, Chief Executive Officer of Precision BioSciences. "Their proven leadership and breadth of experience will undoubtedly prove critical to our gene and cell therapy product development programs.

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Janssen is tapping little-known and privately held Hemera Biosciences for a new gene therapy aimed at reversing a severe disease.

Harvard scientists showed that a three-gene cocktail, by epigenetic reprogramming, could reverse the aging clock in mice retina nerve cells.

Merck is clearly still buzzing about its two-year Dragonfly Therapeutics pact, as it has snapped up a cancer program.